Atrial fibrillation prevalence revisited
|
|
- Amice Watson
- 6 years ago
- Views:
Transcription
1 Original Article Atrial fibrillation prevalence revisited doi: /joim L. Friberg 1,2 & L. Bergfeldt 3 From the 1 Department of Clinical Science, Karolinska Institute, Danderyd Hospital, Stockholm; 2 Department of Cardiology, Danderyd Hospital, Stockholm; and 3 Department of Molecular and Clinical Medicine/Cardiology, Sahlgrenska Academy, University of Gothenburgh, Gothenburg, Sweden Abstract. Friberg L, Bergfeldt L (Karolinska Institute, Danderyd Hospital, Stockholm; Sahlgrenska Academy, University of Gothenburgh, Gothenburg, Sweden.). Atrial fibrillation prevalence revisited. J Intern Med 2013; doi: /joim Background. The estimate of % prevalence of atrial fibrillation in the most recent American guidelines is based mainly on studies including patients with permanent atrial fibrillation (AF), although recent evidence shows that the stroke risk is similar with paroxysmal and persistent AF. Our objective was to determine the prevalence of AF in Sweden, irrespective of type and to what extent patients with AF receive adequate stroke prophylaxis. Method. Retrospective study of patients with a clinical diagnosis of atrial fibrillation between 2005 and 2010 in the national Swedish Patient Register matched with data from the National Prescribed Drugs Register. Results. We identified individuals with a diagnosis of atrial fibrillation. Of these, were still alive on the last day of the inclusion period, signifying a prevalence of clinically diagnosed AF in Sweden of 2.9% of the total adult ( 20 years) population. Only 42% of them had purchased an oral anticoagulant within 6 months of the first presentation with AF during the study period. Those at the highest risk of stroke were those least likely to receive anticoagulant treatment. Undertreatment was common amongst women and individuals >80 years, whilst overtreatment was common amongst young men without risk factors. Conclusion. The prevalence of atrial fibrillation is at least 2.9% of the Swedish adult population, not counting silent atrial fibrillation. The official US figures probably underestimate the magnitude of the problem by a factor of 3 5. More than 80% had risk factors motivating anticoagulation therapy. Keywords: anticoagulation, atrial fibrillation, epidemiology. Introduction Atrial fibrillation (AF) is associated with a 4 5-fold increased risk of stroke [1, 2], a 2 3-fold increased risk of cardiac failure [3], almost a doubling of mortality [4, 5] and impaired quality of life [6]. It is generally recognized as the most common significant dysrhythmia, although the prevalence estimates are highly diverging. The latest version of the American guideline document on AF says, The estimated prevalence of AF is 0.4% to 1.0% in the general population [7] whilst their European counterpart estimates the prevalence to be % of the general population [8]. This variability and uncertainty about the prevalence is in part due to inclusion of different types of AF. Older studies mostly counted patients with permanent AF, which only constitute a minority of all patients with AF [9]. For many years, the general belief was that paroxysmal AF is less hazardous than permanent AF. However, it has been shown that stroke rates are similar in both forms [10 12]. Thus, there is lack of information about the clinically relevant AF prevalence, which is needed for the assessment of its impact on, for example, stroke and heart failure and for planning of future health care. The aim of this study was to determine the prevalence of clinically diagnosed AF in adults in Sweden, irrespective of type (paroxysmal, persistent or permanent) and to determine to what extent patients with AF are receiving adequate stroke prophylaxis. Methods Study population We included all adults ( 20 years) with a primary or secondary diagnosis of AF between 1 July 2005 and 31 December 2010, listed in the national Swedish Patient Register. It covers all hospitals in the coun- ª 2013 The Association for the Publication of the 1
2 try since 1987 and provides complete lists of dates of admissions and discharges with diagnostic codes according to the 10th revision of the International Classification of Diseases (ICD-10), as well as codes for surgical and therapeutic procedures. The Patient Register also includes information about out-patient visits at hospitals and hospital-managed satellite centres, but not about visits in the primary care (general practitioners offices). We used the ICD-10 code I489 to identify individuals with an AF diagnosis. This definition includes both atrial fibrillation and flutter because these dysrhythmias are closely related and also have a similar stroke risk [13]. Each individual was only counted once and there were no exclusion criteria. The date of the first occasion with an AF diagnosis during the inclusion period was used as index date. Diagnoses given prior to index date were used for the characterization of previous and concurrent diseases. We used this background information to calculate each patient s stroke risk score according to the CHADS 2 scheme, which gives 2 points for a previous stroke, TIA or systemic emboli, and one point each for heart failure, hypertension, diabetes and age 75 years [14]. We also calculated the newer CHA2DS2-VASc score, which in addition to the CHADS2 score gives 2 points for age 75, and 1 point each for age years, vascular disease and female sex [1, 15]. The codes used to define these conditions are listed in Appendix S1. Bleeding risk was calculated using a modified HAS- BLED score (16) counting points for hypertension, renal failure, liver disease, thromboembolism, previous bleeding, age 65 years, prescription of ASA or clopidogrel and alcohol abuse defined from a diagnostic code belonging to the alcohol index used for statistical purposes by the National Board of Health and Welfare (see Appendix S1). We had no information about INR values for patients treated with warfarin and had omit giving points for that. Dates of deaths were obtained from the Swedish Population Register. Information about the general population was obtained from the government agency Statistics Sweden. To make our results comparable with other studies in the field, we expressed prevalence as that in the adult population aged 20 years, which on 31 December 2010 was Information about medication was obtained from the National Prescribed Drugs Register. This register automatically stores detailed information about every prescription that is handled in every pharmacy in the country since 1 July 2005 and is therefore almost 100% complete. Medication at baseline was defined as drugs that had been collected at a pharmacy within 90 days of the index date. The only registered oral anticoagulant in Sweden during the study period was warfarin, with phenprocoumon as an alternative on special licence for a very small number of patients intolerant to warfarin. Statistical methods Baseline characteristics were presented descriptively, and differences were tested with t-tests and chi-squared test. P-values <0.05 were considered significant. All analyses were performed in SPSS 20.0 (IBM SPSS Statistics, IBM Corporation, Route 100, Somers, NY 10589, USA). Ethical approval Approval for the study was obtained from the regional ethical committee in Stockholm (EPN 2005/22 21/4, 2008/433 32). Results Prevalence During the 5.5-year inclusion period, unique adult individuals received a hospital diagnosis of AF in Sweden; of them died before the end of that period. Thus, on 31 December 2010, there were living men and women with a diagnosis of AF corresponding to a prevalence of 2.9% of the adult Swedish population. The mean age was years at the index date (men years, women years). Clinical characteristics of those who survived, and of those who died before the end of the inclusion period, are presented in Table 1. The prevalence increased with age up to 14.3% (6168/43 237) at 84 years where after the proportion of individuals with AF appeared to decrease (Fig. 1). The prevalence was higher in men than in women in all age groups (Table 2) and higher in rural areas where the mean age of the population is higher. Thus, prevalence ranged from 2.5% in the Swedish capital Stockholm, where the mean age of the population is 39.0 years, up to 3.5% in the northernmost rural region of Norrbotten, where mean age of the population was 42.4 years. 2 ª 2013 The Association for the Publication of the
3 Table 1 Clinical and demographic characteristics All patients (n = ) Survived (n = ) Died (n = ) Age at index date, years Mean SD Median <65 18% 25% 4% % 28% 12% 75 59% 47% 84% Sex Women 45% 43% 49% Men 55% 57% 51% Risk score CHADS CHA 2 DS 2 -VASc HAS-BLED a Medical history Thromboembolism 21% 16% 30% Heart failure 31% 22% 49% Hypertension 45% 45% 46% Diabetes 17% 14% 21% Vascular disease 23% 19% 33% Prophylaxis at index date Warfarin only 30% 34% 20% ASA only 34% 29% 45% Clopidogrel only 1% 1% 1% Warfarin 12% 15% 7% combos ASA+Clopidogrel 3% 3% 3% None 20% 19% 24% a Modified HAS-BLED without variable labile INR. Comorbidities Over the years, the patients had accumulated a mean of 50.2 diagnoses prior to the index date. In most patients, a few diagnoses reappeared several times in conjunction with new healthcare contacts. At the index date, >80% of the patients had comorbidities which would warrant consideration for stroke prophylaxis according to current American and European guideline recommendations (CHADS 2 score 2 in 82% of patients, CHA 2 DS 2 - VASc score 2 in 83%) [7, 8]. About one-third (34.7%) had high bleeding risk defined as HAS- BLED score 3. Amongst the comorbidities in the risk stratification schemes, hypertension was the most common affecting 45%, followed by heart failure which was found in 31% (Table 3). Stroke prophylaxis Warfarin, alone or in combination with ASA or clopidogrel, was used by 42% of the patients. ASA as single therapy was used by 34% and 20% of the patients had no therapy at all (Table 1). Warfarin use was inversely associated with stroke risk so that those at the highest risk of stroke were the least likely to receive it (Fig. 2). In contrast, ASA use increased in parallel with increasing stroke risk score (Fig. 3). After 80 years of age, warfarin ª 2013 The Association for the Publication of the 3
4 Fig. 1 Prevalence of diagnosed atrial fibrillation in relation to age on 31 December Table 2 Atrial fibrillation prevalence by age and sex amongst patients alive on 31 December 2010 P All (n = ) % Men (n = ) % Women (n = ) % Men vs. women <60 years (n = ) < years (n = ) < years (n = ) < years (n = ) < years (n = 7699) < All ages < Table 3 Comorbidities in relation to age amongst all patients with AF diagnosis Age, years Thromboembolism (n = ) % Heart failure (n = ) % Diabetes (n = ) % Hypertension (n = ) % Vasc. disease (n = ) % <60 (n = ) (n = ) (n = ) (n = ) (n = ) All ages AF, atrial fibrillation. use dropped rapidly, and at 90 and higher less than 10% received warfarin (Table 4, Fig. 4). Men were treated with warfarin more often than women (46% vs. 37%, P < ). Warfarin use was relatively common amongst young men with no risk points. In the very low-risk group with 0 points on CHA 2 DS 2 -VASc, 38% had warfarin. Cardioversion was not the primary reason for treatment in this group because only 11% of them (2347/ ) were cardioverted during the study period. Discussion The present prevalence estimate of at least 2.9% is considerably higher than the current official estimate of % in the 2011 guideline update from the American College of Cardiology/American Heart Association/Heart Rhythm Society [7]. The American guidelines refer to two sources. One is a meta-analysis from 1995 [18] where the authors admit that there were so few elderly patients in the 4 ª 2013 The Association for the Publication of the
5 data on elderly patients was due to upper age limits for inclusions in the studies. The second reference is the ATRIA study, which only counted patients with nontransient atrial fibrillation, that is, permanent AF, which also had to be the principal diagnosis [17]. In the Euro Heart Survey [9] only 30% of the patients had permanent AF and would have fulfilled the ATRIA criteria. Furthermore, the criterion that AF had to be the principal diagnosis presumably resulted in the exclusion of patients with many comorbidities who are likely to receive some other more urgent diagnosis at discharge, rather than AF. Thus, many patients with AF were not counted in these earlier prevalence studies performed at a time when nonpermanent AF was believed to carry a low risk for stroke. Observations on stroke prophylaxis Fig. 2 Warfarin use amongst men and women in relation to CHA 2 DS 2 -VASc and HAS-BLED score. Only 42% of the patients had purchased warfarin at least once during a 6-month period framing the index date, although 83% of them had a risk score indicating that they would have benefited from anticoagulation therapy, unless there were strong reasons against it [19, 20]. Paradoxically, those at the highest risk of stroke were those least likely to receive warfarin treatment. There was an almost linear decrease in the likelihood of receiving warfarin with increasing stroke risk. In contrast, the likelihood for receiving ASA increased almost linearly with increasing risk. One way to interpret this is that prescribing doctors recognize the high stroke risk in patients with high-risk scores, but that they consider them too frail for anticoagulants and chose ASA instead. ASA is often perceived as a milder treatment option, although the protective effect is very weak and the bleeding risk is about the same as with well-managed warfarin therapy [8, 21]. Warfarin treatment rapidly declined after the age of 80, although it is well recognized that advanced age is one of the most important stroke risk factors. Women were less often treated with warfarin than men at all ages (37% vs. 46%), despite their higher stroke risk [22, 23]. The reason for this is unclear and calls for further investigation and measures to improve current practices. Fig. 3 ASA use amongst men and women in relation to CHA 2 DS 2 -VASc and HAS-BLED score. studies that the they had to arbitrarily chose a prevalence rate of 10% for all persons older than 80 years, which is obviously too low. The lack of Generalizability of the results The prevalence of AF within a population is clearly related to the proportion of elderly individuals. In our study, we found that the regional prevalence varied between 2.5% and 3.5% between two ª 2013 The Association for the Publication of the 5
6 Table 4 Warfarin use at the index date amongst all patients with AF diagnosis All (n = ) % Men (n = ) % Women (n = ) % P Men vs. women <60 (n = ) < (n = ) < (n = ) < (n = ) < (n = ) < All ages < AF, atrial fibrillation. Fig. 4 Warfarin use in relation to age and sex amongst all patients with atrial fibrillation (AF). regions where the mean ages of the populations only differed by 3.4 years. In countries with younger population structures than the Swedish, the overall AF prevalence will probably be lower, but age and sex stratified prevalence may still be similar. Considering that many countries have rapidly ageing populations the information about the age and sex stratified prevalence is relevant for the dimensioning of the future healthcare system, especially with regard to the association with stroke and heart failure, which are the major cost drivers [24]. It has been suggested that AF prevalence may vary according to the ethnic background, which is not registered for Swedish residents, unlike in the United States and many other countries. Although Sweden has become more multicultural in recent decades, the Swedish population still consists mainly of Caucasians. According to the official statistical agency Statistics, Sweden only 14% of the inhabitants were born abroad, and of these, the majority were born in Europe [25]. The results of our study may therefore not be directly applicable to a country with a predominantly non-caucasian population. Limitations It has not been possible for us to verify the AF diagnoses by ECG recordings. However, a recent validation study of the Swedish Patient Register could confirm AF in 97% of a random sample [26]. The extent of under diagnosis is not known and would require population screening to be determined. However, in the greater Gothenburg area (Vaestra Goetaland County) of 1.2 million adults, 22% of the patients with AF were cared for only in primary care (Staffan Bj orck, personal communication), which extrapolated to the whole country suggests a prevalence of 3.5%. Patients with several more urgent or serious diagnoses may have been left without an AF diagnosis at discharge. Underreporting of concomitant and previous diseases may have occurred for similar reasons. This may have affected the risk scores for ischaemic stroke, CHADS 2 and CHA 2 DS 2 -VASc, giving 6 ª 2013 The Association for the Publication of the
7 patients falsely lower risk scores than they actually should have had. Conclusion The prevalence of AF is at least 2.9% of the Swedish adult population. The current US guidelines probably underestimate the magnitude of the problem by a factor 3 5 and therefore also the fraction of individuals at risk of AF-related stroke, who might benefit from prophylactic therapy with oral anticoagulants. Conflict of interest statement Both authors have completed the ICMJE uniform disclosure form at pdf (available on request from the corresponding author) and declare: the submitted work was supported by The Swedish Heart and Lung Foundation and The Stockholm County Council; no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years; Outside of the submitted work, Karolinska Institute received grants in support of LF s research from Boehringer-Ingelheim, Sanofi- Aventis, Bristol-Myers-Squibb and Bayer. LF has participated in advisory boards with Boehringer- Ingelheim and Sanofi-Aventis. LB has participated in advisory boards with Sanofi-Aventis, Boehringer-Ingelheim and MSD, and given lectures supported by Sanofi-Aventis and MSD. Authorship Both authors participated in the drafting of the study and in revisions of the manuscript. LF prepared the data file, made the statistical analyses and wrote the first manuscript draft. LF takes full responsibility for the accuracy of the statistical analyses. Funding The Swedish Heart and Lung Foundation, and the Stockholm County Council. The manuscript conforms to the STROBE statement for cross-sectional studies. References 1 Flegel KM, Shipley MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation. Lancet 1987; 1: Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978; 28: Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113: Benjamin EJ, Wolf PA, D Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: Friberg L, Hammar N, Pettersson H, Rosenqvist M. Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF). Eur Heart J 2007; 28: Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 2006; 119: 448.e Fuster V, Ryden LE, Cannom DS et al ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011; 123: e Camm AJ, Lip GY, De Caterina R et al focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation Developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14: Nieuwlaat R, Capucci A, Camm AJ et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26: Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke prevention in atrial fibrillation investigators. J Am Coll Cardiol 2000; 35: Hohnloser S, Pajitnev D, Pogue J et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy An ACTIVE W substudy. J Am Coll Cardiol 2007; 50: Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J 2010; 31: Ludvigsson JF, Andersson E, Ekbom A et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011; 11: Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year ª 2013 The Association for the Publication of the 7
8 risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010 Nov; 138: Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155: Singer DE, Chang Y, Fang MC et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 2012; 125: Olesen JB, Lip GY, Lindhardsen J et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a real world nationwide cohort study. Thromb Haemost 2011; 106: Hughes M, Lip GY. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99: Friberg L, Benson L, Rosenqvist M, Lip GY. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ 2012; 344: e Ericson L, Bergfeldt L, Bjorholt I. Atrial fibrillation: the cost of illness in Sweden. Eur J Health Econ 2011; 12: StatisticsSweden. Description of the population 2008 (Beskrivning av Sveriges befolkning 2008), Smith JG, Platonov PG, Hedblad B, Engstrom G, Melander O. Atrial fibrillation in the Malmo Diet and Cancer study: a study of occurrence, risk factors and diagnostic validity. Eur J Epidemiol 2010; 25: Correspondence: Leif Friberg, MD, PhD, Storskogsv agen 5, SE Stockholm, Sweden. (fax: ; leif.friberg@ki.se). Supporting Information Additional Supporting Information may be found in the online version of this article: Appendix S1. Definition of diagnoses by ICD-10 codes and Swedish surgical procedural codes. 8 ª 2013 The Association for the Publication of the
Atrial Fibrillation, Stroke Risk, and Warfarin Therapy Revisited A Population-Based Study
Atrial Fibrillation, Stroke Risk, and Warfarin Therapy Revisited A Population-Based Study Staffan Björck, MD, PhD; Bo Palaszewski, PhD; Leif Friberg, MD, PhD; Lennart Bergfeldt, MD, PhD Background and
More informationAtrial Fibrillation, Stroke Risk, and Warfarin Therapy Revisited A Population-Based Study
Atrial Fibrillation, Stroke Risk, and Warfarin Therapy Revisited A Population-Based Study Staffan Björck, MD, PhD; Bo Palaszewski, PhD; Leif Friberg, MD, PhD; Lennart Bergfeldt, MD, PhD Downloaded from
More information2012 focussed update of the ESC Guidelines for the Management of Atrial Fibrillation
European Heart Journal 2012 doi:10.1093/eurheartj/ehs253 ESC 2012 2012 focussed update of the ESC Guidelines for the Management of Atrial Fibrillation An update of the 2010 ESC Guidelines for the Management
More informationObjectives. Falling Down on Warfarin Therapy. CHADS 2 Score. CHADS 2 & CHA 2 DS 2 -VASc Score. HAS-BLED Score 04/08/2014. Real World Application
Falling Down on Warfarin Therapy David Andrew Jacob, PharmD Pharmacy Resident 2013-2014 Dayton VA Medical Center Dayton, Ohio Objectives Describe CHADS 2 score and the decision to anticoagulate patients
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationWeighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated?
Weighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated? Albert L. Waldo, MD, PhD (Hon) The Walter H. Pritchard Professor of Cardiology, Professor of Medicine,and
More informationAtrial fibrillation patients do not benefit from acetylsalicylic acid
Europace (2014) 16, 631 638 doi:10.1093/europace/eut333 CLINICAL RESEARCH Atrial fibrillation Atrial fibrillation patients do not benefit from acetylsalicylic acid Sara Själander 1 *, Anders Själander
More informationHigh Prevalence of Atrial Fibrillation Among Patients With Ischemic Stroke
High Prevalence of Atrial Fibrillation Among Patients With Ischemic Stroke Leif Friberg, PhD; Mårten Rosenqvist, PhD; Arne Lindgren, PhD; Andreas Terént, PhD; Bo Norrving, PhD; Kjell Asplund, PhD Background
More informationDraft Agreed by Cardiovascular Working Party 25 Jan Adoption by CHMP for release for consultation 17 Feb 2011
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 London, 25 January 2011 EMA/CHMP/68875/2011 Committee for Medicinal Products for Human Use (CHMP) Concept paper on the need for a guideline on clinical investigation
More informationEvaluate Risk of Stroke & Bleeding in AF Patients
XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation
More informationAtrial fibrillation (AF) is the most prevalent sustained
Clinical Sciences Atrial Fibrillation and the Risk of Ischemic Stroke Does It Still Matter in Patients With a CHA 2 DS 2 -VASc Score of 0 or 1? Tze-Fan Chao, MD*; Chia-Jen Liu, MD*; Su-Jung Chen, MD; Kang-Ling
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Olesen JB, Lip GYH, Kamper A-L, et al. Stroke and bleeding
More informationTable S10 Mortality Study
Table S10 Mortality Study Framingham Heart Study, Benjamin (1998) 1 ELAT Study, Austria and Serbia Stollberger (2004) 2 Copenhagen City Heart study, Denmark Friberg (2004) 3 Patel (2004) 4 Invited residents
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationWhere a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
Using the CHA2DS2-VASc score for stroke prevention in atrial fibrillation Nielsen, Peter Brønnum; Skjøth, Flemming; Rasmussen, Lars Hvilsted; Larsen, Torben Bjerregaard; Lip, Gregory DOI: 10.1016/j.cjca.2015.01.034
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationStratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto
Fibrillazione atriale: rischio tromboembolico, Venezia - 27/28 Novembre 2015 Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto Antonio Raviele, MD, FESC,
More informationIS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS?
IS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS? J.Y. LE HEUZEY Georges Pompidou Hospital, René Descartes University, Paris H E G P Munich, August 27, 2012 Disclosure Consultant / Conferences / Advisory
More informationMMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin?
MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin? Daniel E. Singer, MD Massachusetts General Hospital Harvard Medical School 1 Speaker Disclosure Information DISCLOSURE
More informationHigh Prevalence of Atrial Fibrillation Among Patients With Ischemic Stroke
High Prevalence of Atrial Fibrillation Among Patients With Ischemic Stroke Leif Friberg, PhD; Mårten Rosenqvist, PhD; Arne Lindgren, PhD; Andreas Terént, PhD; Bo Norrving, PhD; Kjell Asplund, PhD Downloaded
More informationReducing the Risk of Stroke Associated With Nonvalvular Atrial Fibrillation in the VHA
DECEMBER 21 VOL. 27 SUPPL. 1 A SUPPLEMENT TO www.fedprac.com Reducing the Risk of Stroke Associated With Nonvalvular Atrial Fibrillation in the VHA Diagnosing and Treating Atrial Fibrillation in the VHA
More informationStroke risk in atrial fibrillation: Do we anticoagulate CHADS 2 or CHA 2 DS 2 -VASc 1, or higher?
Current Controversies 1165 Stroke risk in atrial fibrillation: Do we anticoagulate CHADS 2 or CHA 2 DS 2 -VASc 1, or higher? Jonas Bjerring Olesen 1 ; Christian Torp-Pedersen 2 1 Department of Cardiology,
More informationRoopinder K Sandhu, 1 Jeffrey A Bakal, 2 Justin A Ezekowitz, 1,2 Finlay A McAlister 3 ORIGINAL ARTICLE. Heart rhythm disorders
< Additional tables are published online only. To view these files please visit the journal online (http://heart.bmj. com). 1 Department of Cardiology, Mazankowski Alberta Heart Institute, University of
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationThe HEMORR 2 HAGES, ATRIA and the HAS-BLED bleeding risk prediction scores in anticoagulated atrial fibrillation patients : The AMADEUS study
The HEMORR 2 HAGES, ATRIA and the HAS-BLED bleeding risk prediction scores in anticoagulated atrial fibrillation patients : The AMADEUS study Apostolakis S 1, Lane DA 1, Buller H 2, Lip GY 1 1 University
More informationWhat s New in the AF Guidelines
Impact on New AF Guidelines on Heart Failure Management Gothenburg - May 22 nd 2011 Europace (2010) 12, 1360-420 http://europace.oxfordjournals.org JACC (2011) 57, 223-42 http://www.cardiosource.org What
More informationAtrial Fibrillation Etiologies and Treatment. Shawn Liu Learner Centered Learning Goal
Atrial Fibrillation Etiologies and Treatment Shawn Liu Learner Centered Learning Goal Pathophysiology Defined by the absence of coordinated atrial systole Results from multiple reentrant electrical waves
More informationConsequences of stroke and AF
Consequences of stroke and AF Lorenzo G Mantovani Center of Pharmacoeconomics University of Naples Center for Public Health Research University of Milan Bicocca Questions Is stroke frequent? Is stroke
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationStudy period Total sample size (% women) 899 (37.7%) Warfarin Aspirin
Table S2 Sex- specific differences in oral anticoagulant prescription for stroke prevention in AF Total sample size (% women) Anticoagulant(s) studied Gage (2000) 1 Missouri, USA Discharged during 597
More informationAtrial fibrillation (AF) is the most common sustained cardiac
Comparison of Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Christopher A. Aakre, MD; Christopher J. McLeod, MBChB, PhD; Stephen S. Cha, MS; Teresa S.M.
More informationPrevalence (%) Table S4 Prevalence of AF in women and men, age- specific Study name/country Study population Study period Age group
Table S4 Prevalence of AF in and men, age- specific Study name/country Yunnan Province, China Random sample of government Guo (2015) 1 medical insurance plan Age 20 years Spain Gomez- Doblas (2014) 2 The
More informationManagement of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근
Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Case (2011, 5) 74-years old gentleman Exertional chest pain Warfarin with good INR control Ex-smoker, social(?)
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationProtocol Number K16. Version 1.2 September 29 th, Study promoted by Fondazione per il Tuo cuore - HCF Onlus
Protocol Number K16 Version 1.2 September 29 th, 2015 Study promoted by Fondazione per il Tuo cuore - HCF Onlus TABLE OF CONTENTS Signature Page for Chairman and Co-Chairman of the study... 3 Signature
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation
Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation August 2008 This technology summary is based on information available at the time of
More informationIncidence of Ischemic Stroke in Japanese Patients With Atrial Fibrillation Not Receiving Anticoagulation Therapy
432 SUZUKI S et al. Circulation Journal ORIGINAL ARTICLE Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Stroke Incidence of Ischemic Stroke in Japanese Patients With Atrial
More informationA COhort of antithrombotic use and. atrial fibrillation in Thailand (COOL AF Thailand)
A COhort of antithrombotic use and Optimal INR Level in patients with nonvalvular atrial fibrillation in Thailand (COOL AF Thailand) Prevalence of Atrial Fibrillation Number of AF Patients Predicted to
More informationHAS-BLED. Ron Pisters, MD Maastricht University Medical Centre (NL) No conflict of interest
HAS-BLED Ron Pisters, MD Maastricht University Medical Centre (NL) No conflict of interest r.pisters@mumc.nl Background major bleeding risk High stroke risk frequently warrants use of oral anticoagulation
More informationKCS Congress: Impact through collaboration
Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact
More informationAF stroke prevention in the Canadian context
AF stroke prevention in the Canadian context 5 th Annual State of the Heart Toronto, May 31, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology Toronto General Hospital, University Health Network
More informationUS FDA Approves Pradaxa (dabigatran etexilate) a breakthrough treatment for stroke risk reduction in non-valvular atrial fibrillation
Press Release For non-us Healthcare Media Boehringer Ingelheim GmbH Corporate Communications US FDA Approves Pradaxa (dabigatran etexilate) a breakthrough treatment for stroke risk reduction in non-valvular
More informationRefining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach
CHEST Original Research Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach The Euro Heart Survey on Atrial Fibrillation
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationL. Fauchier (1), S. Taillandier (1), I. Lagrenade (1), C. Pellegrin (1), L. Gorin (1), A. Bernard (1), B. Rauzy (1), D. Babuty (1), GYL.
Prognosis in patients with atrial fibrillation and CHA 2 DS 2 VASc score=0 in a real world community based cohort study: Loire Valley Atrial Fibrillation project L. Fauchier (1), S. Taillandier (1), I.
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More informationAnticoagulation and Mortality Rates among Hospitalized Patients with Atrial Fibrillation
THIEME Original Article e33 Anticoagulation and Mortality Rates among Hospitalized Patients with Atrial Fibrillation Gregory Piazza 1 Shelley Hurwitz 2 Lindsay M. Harrigan 1 Kathryn L. Jenkins 1 Benjamin
More informationDavis, LL. (2013) Preventing stroke in patients with atrial fibrillation. The Nurse Practitioner, 38(11):
Preventing stroke in patients with atrial fibrillation By: Leslie L. Davis Davis, LL. (2013) Preventing stroke in patients with atrial fibrillation. The Nurse Practitioner, 38(11): 24-31. This is a non-final
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationThe likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines
Europace (2010) 12, 779 784 doi:10.1093/europace/euq080 CLINICAL RESEARCH Atrial Fibrillation Clinical Issues The likelihood of decreasing strokes in atrial fibrillation patients by strict application
More informationAlthough several risk factors for stroke are responsive to
n reports n A Pharmacoeconomic Perspective on Stroke Prevention in Atrial Fibrillation A. Mark Fendrick, MD Abstract Atrial fibrillation (AF) is predictive of higher costs for stroke care, in part due
More informationCondition Congestive heart failure I11.0; I13.0; I13.2; I42.0; I50 CO3C Left ventricular dysfunction I50.1; I50.9 E11 1; E11 9
Comparative effectiveness and safety of non-vitamin K antagonists oral anticoagulants (OACs) and warfarin in daily clinical practice: A propensity weighted nationwide cohort study. Supplementary material
More informationAtrial fibrillation: a key determinant in the cardiovascular risk continuum. u Prof. Joseph S. Alpert u Arizona, USA
Atrial fibrillation: a key determinant in the cardiovascular risk continuum u Prof. Joseph S. Alpert u Arizona, USA Disclosures u No major conflicts of interest: all honoraria
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Risk Stratification in Antithrombotic Management: Is There Room for Improvement? August 28, 2011 Elaine M. Hylek, MD, MPH Boston University DISCLOSURE INFORMATION Research:
More informationAntithrombotic Therapy in Patients with Atrial Fibrillation
Antithrombotic Therapy in Patients with Atrial Fibrillation June Soo Kim, M.D., Ph.D. Department of Medicine Cardiac & Vascular Center, Samsung Medical Center Sungkyunkwan University School of Medicine
More informationAtrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie
Atrial Fibrillation Implementation challenges Lesley Edgar Ross Maconachie Atrial Fibrillation Most common heart rhythm disturbance Rapid and irregular electrical signals Reduced efficiency of blood flow
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationStroke-free duration and stroke risk in patients with atrial fibrillation: simulation using a Bayesian inference
Asian Biomedicine Vol. 3 No. 4 August 2009; 445-450 Brief Communication (Original) Stroke-free duration and stroke risk in patients with atrial fibrillation: simulation using a Bayesian inference Tomoki
More informationStroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
More informationMY APPROACH to the use of NOACs for stroke prevention in patients with atrial fibrillation Lip, Gregory
MY APPROACH to the use of NOACs for stroke prevention in patients with atrial fibrillation Lip, Gregory DOI: 10.1016/j.tcm.2014.05.012 License: Other (please specify with Rights Statement) Document Version
More informationControversies in Risk Stratification
Controversies in Risk Stratification Things are not as simple as they seem Banff 2017 2015 MFMER 3494750-5 Relative importance Triggers vs Substrate in Pathophysiology of AF AF burden Paroxysmal? Persistent?
More informationWhat are the risk factors for AF?
Susan Mayor was paid in her capacity as a medical writer for her time to research and write this article for Boehringer Ingelheim. This article has been reviewed by Boehringer Ingelheim to ensure compliance
More informationFølgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved
. Følgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved tilladelse Antithrombotic therapy in Atrial Fibrillation
More informationHigh Incidence of Atrial Fibrillation or Flutter in Stroke Patients Who Have the Clinical Risk Factors for Stroke
High Incidence of Atrial Fibrillation or Flutter in Stroke Patients Who Have the Clinical Risk Factors for Stroke Jacob I. Haft MD 1, Louis E. Teichholz MD 2 1 Senior Attending in Cardiology HUMC Clinical
More informationDS 2. 72,452 subjects who had an ATRIA score of 0 to 5 (low risk).
[ Original Research Cardiovascular Disease ] The Value of the European Society of Cardiology Guidelines for Refining Stroke Risk Stratification in Patients With Atrial Fibrillation Categorized as Low Risk
More informationManaging Atrial Fibrillation in the Heart Failure Patient
Managing Atrial Fibrillation in the Heart Failure Patient Jonathan S. Steinberg, MD Professor of Medicine (adj) University of Rochester School of Medicine & Dentistry Director, Arrhythmia Institute Valley
More informationThe HAS-BLED Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis
Review The HAS-BLED Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis Address for correspondence: Kui Hong, MD Cardiovascular
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationORIGINAL ARTICLE. Introduction
doi: 10.2169/internalmedicine.0021-17 Intern Med 57: 2295-2300, 2018 http://internmed.jp ORIGINAL ARTICLE Atrial Fibrillation Had Less Impact on the Risk of Ischemic Stroke in Non-anticoagulated Patients
More informationAtrial Fibrillation Key Messages
Atrial Fibrillation Key Messages Dr Matthew Fay Westcliffe Medical Practice National Clinical Lead NHS Improvement www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Clinical Events
More informationAn update on managing patients with atrial fibrillation
Cardiovascular system haematology An update on managing patients with atrial fibrillation Most patients with atrial fibrillation can be managed in primary care. Patients should be referred for an initial
More informationAtrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
More informationUse of Warfarin in Elderly Patients With Non-Valvular Atrial Fibrillation
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Arrhythmia/Electrophysiology Use of Warfarin in Elderly Patients With Non-Valvular Atrial
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationSubclinical AF: Implications of device based episodes
Subclinical AF: Implications of device based episodes Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Clinical Trials and Consulting: Medtronic, Boston Scientific
More informationStroke Prevention & Atrial Fibrillation. Susanne Christie Arrhythmia Nurse Specialist 24 th September 2015
Stroke Prevention & Atrial Fibrillation Susanne Christie Arrhythmia Nurse Specialist 24 th September 2015 Learning Outcomes What is Atrial Fibrillation? Why is Atrial Fibrillation important? What causes
More informationIdentifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated?
Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated? Renato D. Lopes, MD MHS PhD Professor of Medicine Division of Cardiology Duke Clinical
More informationReviews. Can We Predict Stroke in Atrial Fibrillation? Gregory Y.H. Lip, MD
Reviews Can We Predict Stroke in Atrial Fibrillation? Gregory Y.H. Lip, MD Centre for Cardiovascular Sciences, University of Birmingham, City Hospital, Birmingham, United Kingdom Address for correspondence:
More informationACC/AHA/Physician Consortium Clinical Performance Measures for Adults with Nonvalvular Atria Fibrillation or Atrial Flutter
ACC/AHA/Physician Consortium Clinical Performance Measures for Adults with Nonvalvular Atria Fibrillation or Atrial Flutter A Report of the American College of Cardiology/American Heart Association Task
More informationWarfarin therapy for atrial fibrillation in general practice is bleeding risk underestimated? 175 9
Original article Warfarin therapy for atrial fibrillation in general practice is bleeding risk underestimated? 175 9 BACKGROUND Atrial fibrillation increases by fivefold the risk for thromboembolic stroke.
More informationClinical Investigations
Clinical Investigations Benefit of Anticoagulation Therapy in Hyperthyroidism-Related Atrial Fibrillation Address for correspondence: Chung-Wah Siu, MD Cardiology Division The University of Hong Kong Hong
More informationExternal Validity of the ARISTOTLE Trial in Real-Life Atrial Fibrillation Patients
ORIGINAL RESEARCH ARTICLE External Validity of the ARISTOTLE Trial in Real-Life Atrial Fibrillation Patients Lovisa H agg, Cecilia Johansson, Jan-Hakan Jansson & Lars Johansson Skelleftea Research Unit,
More informationΣεμινάπιο Ομάδων Δπγαζίαρ ΟΜΑΓΑ ΔΡΓΑΣΙΑΣ ΗΛΔΚΤΡΟΦΥΣΙΟΛΟΓΙΑΣ ΚΑΙ ΒΗΜΑΤΟΓΟΤΗΣΗΣ Κολπική μαπμαπςγή
Σεμινάπιο Ομάδων Δπγαζίαρ ΟΜΑΓΑ ΔΡΓΑΣΙΑΣ ΗΛΔΚΤΡΟΦΥΣΙΟΛΟΓΙΑΣ ΚΑΙ ΒΗΜΑΤΟΓΟΤΗΣΗΣ Κολπική μαπμαπςγή Δξελίξειρ ζηην ανηιπηκηική αγωγή ζε αζθενείρ με κολπική μαπμαπςγή Ξςδώναρ Σωηήπιορ Μονάδα Δμθπαγμάηων και
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationAtrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently
More informationProfessor DA Fitzmaurice Primary Care Clinical Sciences University of Birmingham
New Guidelines for SPAF Professor DA Fitzmaurice Primary Care Clinical Sciences University of Birmingham Stroke prevention and atrial fibrillation Epidemiology of atrial fibrillation How common is it?
More informationFall risk and anticoagulation for atrial fibrillation in the elderly: A delicate balance
REVIEW TRACY HAGERTY, MD Fellow in Cardiology, Washington University School of Medicine, St. Louis, MO MICHAEL W. RICH, MD Director, Cardiac Rapid Evaluation Unit, Barnes-Jewish Hospital; Professor of
More informationManagement of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39
Management of ATRIAL FIBRILLATION in general practice 22 BPJ Issue 39 What is atrial fibrillation? Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in primary care. It is often
More informationRisk Stratification for Stroke Prevention in Patients with Atrial Fibrillation: The emerging role of biomarkers
Risk Stratification for Stroke Prevention in Patients with Atrial Fibrillation: The emerging role of biomarkers Banff 2013 CP1221547-8 Meta-Analysis of Stroke 5 Randomized Trials Placebo Stroke Rate 4.5%/yr
More informationThromboembolism During Sinus Rhythm in Patients with a History of Atrial Fibrillation
48 th Annual New York Cardiovascular Symposium Thromboembolism During Sinus Rhythm in Patients with a History of Atrial Fibrillation Is Left Atrial Appendage Dysfunction Sufficient to Generate Clots? December
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Clinical guideline for the management of atrial fibrillation
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE 1 Guideline title SCOPE Clinical guideline for the management of atrial fibrillation 1.1 Short title Atrial fibrillation 2 Background a) The National Institute
More informationWhere a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
Specific risk scores for specific purposes: Use CHA2DS2-VASc for assessing stroke risk, and use HAS-BLED for assessing bleeding risk in atrial fibrillation Dzeshka, Mikhail S.; Lip, Gregory DOI: 10.1016/j.thromres.2014.06.003
More informationTrends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation,
Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017 Junya Zhu, PhD Department of Health Policy and Management January 23, 2018 Acknowledgments Co-Authors G.
More informationGRASP-AF- The National Picture. Dr Richard Healicon National Improvement Lead Ian Robson Senior Analyst NHS Improvement February 2012
GRASP-AF- The National Picture Dr Richard Healicon National Improvement Lead Ian Robson Senior Analyst NHS Improvement February 2012 Outline AF and stroke Objective Management of stroke risk Stroke risk
More informationManagement of atrial fibrillation in diabetes
Stephen Dobbin 1 MBChB, MRCP, Cardiology SpR Miles Fisher 2 MD, FRCP, Consultant Physician Gerry McKay 2 BSc (Hons), FRCP, Consultant Physician 1 Department of Cardiology, Golden Jubilee National Hospital,
More informationI have nothing to disclose.
I have nothing to disclose. Atrial fibrillation in octogenarians and beyond. The magnitude of the problem Etienne Aliot University of Nancy France Population ageing World Population Ageing 1950-2050 Age>
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationStroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease
original article Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease Jonas Bjerring Olesen, M.D., Gregory Y.H. Lip, M.D., Anne-Lise Kamper, M.D., D.M.Sc., Kristine Hommel, M.D., Lars
More informationCost-Effectiveness of Dabigatran Exilate in Treatment of Atrial Fibrillation
Cost-Effectiveness of Dabigatran Exilate in Treatment of Atrial Fibrillation Giovanni Galvani, Alberto Grassetto, Stefania Sterlicchio, Sakis Themistoclakis, Andrea Venturini, Giampaolo Zoffoli, Domenico
More information